BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD
Taking everything into account, BMRN scores 7 out of 10 in our fundamental rating. BMRN was compared to 572 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. BMRN has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make BMRN suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BMRN reported negative net income in multiple years.
Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
BMRN has a better Return On Assets (4.70%) than 94.87% of its industry peers.
With an excellent Return On Equity value of 5.95%, BMRN belongs to the best of the industry, outperforming 94.69% of the companies in the same industry.
The Return On Invested Capital of BMRN (5.27%) is better than 94.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROIC | 5.27% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BMRN's Profit Margin of 11.71% is amongst the best of the industry. BMRN outperforms 95.58% of its industry peers.
In the last couple of years the Profit Margin of BMRN has declined.
BMRN's Operating Margin of 14.88% is amongst the best of the industry. BMRN outperforms 95.93% of its industry peers.
BMRN's Gross Margin of 78.95% is amongst the best of the industry. BMRN outperforms 86.55% of its industry peers.
BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
BMRN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
BMRN has an Altman-Z score of 5.85. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BMRN (5.85) is better than 82.12% of its industry peers.
BMRN has a debt to FCF ratio of 1.98. This is a very positive value and a sign of high solvency as it would only need 1.98 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.98, BMRN belongs to the top of the industry, outperforming 95.22% of the companies in the same industry.
A Debt/Equity ratio of 0.11 indicates that BMRN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.11, BMRN is not doing good in the industry: 66.73% of the companies in the same industry are doing better.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Altman-Z | 5.85 |
ROIC/WACC0.51
WACC10.43%
2.3 Liquidity
A Current Ratio of 4.27 indicates that BMRN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.27, BMRN is in line with its industry, outperforming 48.32% of the companies in the same industry.
A Quick Ratio of 2.62 indicates that BMRN has no problem at all paying its short term obligations.
The Quick ratio of BMRN (2.62) is worse than 69.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 127.27% over the past year.
The earnings per share for BMRN have been decreasing by -40.67% on average. This is quite bad
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 19.14% in the last year.
The Revenue has been growing by 10.16% on average over the past years. This is quite good.
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.28%
3.2 Future
The Earnings Per Share is expected to grow by 48.41% on average over the next years. This is a very strong growth
BMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.77% yearly.
EPS Next Y119.97%
EPS Next 2Y78.8%
EPS Next 3Y61.96%
EPS Next 5Y48.41%
Revenue Next Year17.05%
Revenue Next 2Y13.53%
Revenue Next 3Y12.46%
Revenue Next 5Y9.77%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 35.27, BMRN can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.51% of the companies in the same industry.
BMRN is valuated rather expensively when we compare the Price/Earnings ratio to 28.58, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 20.33 indicates a rather expensive valuation of BMRN.
94.87% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
BMRN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.47.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.27 | ||
| Fwd PE | 20.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 95.40% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.11 | ||
| EV/EBITDA | 21.19 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 61.96% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y78.8%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (1/24/2025, 8:27:54 PM)
After market: 61.9999 +0.27 (+0.44%)61.73
-0.46 (-0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.09%
Inst Owner Change0.32%
Ins Owners0.7%
Ins Owner Change0.57%
Market Cap11.76B
Analysts81.14
Price Target98.93 (60.26%)
Short Float %2.4%
Short Ratio3.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.72%
Min EPS beat(2)4.22%
Max EPS beat(2)57.23%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-24.46%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)28.16%
EPS beat(12)9
Avg EPS beat(12)-8.43%
EPS beat(16)13
Avg EPS beat(16)29.42%
Revenue beat(2)2
Avg Revenue beat(2)4.93%
Min Revenue beat(2)4.42%
Max Revenue beat(2)5.44%
Revenue beat(4)2
Avg Revenue beat(4)1.73%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)5
Avg Revenue beat(12)-0.4%
Revenue beat(16)8
Avg Revenue beat(16)0.27%
PT rev (1m)-0.38%
PT rev (3m)-4.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.71%
EPS NY rev (1m)0%
EPS NY rev (3m)0.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.34%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.27 | ||
| Fwd PE | 20.33 | ||
| P/S | 4.27 | ||
| P/FCF | 39.11 | ||
| P/OCF | 28.37 | ||
| P/B | 2.17 | ||
| P/tB | 2.37 | ||
| EV/EBITDA | 21.19 |
EPS(TTM)1.75
EY2.83%
EPS(NY)3.04
Fwd EY4.92%
FCF(TTM)1.58
FCFY2.56%
OCF(TTM)2.18
OCFY3.52%
SpS14.44
BVpS28.4
TBVpS26.01
PEG (NY)0.29
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROCE | 6.68% | ||
| ROIC | 5.27% | ||
| ROICexc | 6.22% | ||
| ROICexgc | 6.81% | ||
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% | ||
| FCFM | 10.93% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
F-Score8
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Debt/EBITDA | 1.17 | ||
| Cap/Depr | 114.17% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 39.55 | ||
| Cash Conversion | 81.42% | ||
| Profit Quality | 93.35% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 5.85 |
F-Score8
WACC10.43%
ROIC/WACC0.51
Cap/Depr(3y)114.13%
Cap/Depr(5y)125.65%
Cap/Sales(3y)5.73%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
EPS Next Y119.97%
EPS Next 2Y78.8%
EPS Next 3Y61.96%
EPS Next 5Y48.41%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.28%
Revenue Next Year17.05%
Revenue Next 2Y13.53%
Revenue Next 3Y12.46%
Revenue Next 5Y9.77%
EBIT growth 1Y243.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year191.82%
EBIT Next 3Y78.47%
EBIT Next 5Y46.56%
FCF growth 1Y639.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.12%
OCF growth 3Y23.09%
OCF growth 5Y51.13%